TGF-beta1 as a Killer Cell Attractant After Chemotherapy
Author Information
Author(s): Y Kuramitsu, M Nishibel, M Kobayashi, Y Togashi, L Yuan, M Takizawa, F Okada, M Hosokawa
Primary Institution: Cancer Institute, Hokkaido University School of Medicine
Hypothesis
Does TGF-beta1 produced in tumor tissue after chemotherapy enhance the accumulation of lymphokine-activated killer (LAK) cells in tumors?
Conclusion
TGF-beta1 produced in tumor tissues after chemotherapy acts as a chemotactic factor for LAK cells, enhancing their accumulation in tumors.
Supporting Evidence
- TGF-beta1 was detected in tumor tissues treated with cyclophosphamide, indicating its production after chemotherapy.
- LAK-attractant activity was significantly higher in conditioned media from tumors treated with cyclophosphamide compared to untreated tumors.
- Recombinant human TGF-beta1 showed LAK-attractant activity at concentrations of 0.1 ng/ml and 1 ng/ml.
Takeaway
After chemotherapy, a substance called TGF-beta1 helps special immune cells called LAK cells find and gather in tumors, which might help fight cancer better.
Methodology
The study used an under agarose migration assay to measure the chemotactic activity of conditioned media from tumor tissues treated with various anti-cancer drugs.
Participant Demographics
Female C57BL/6 mice, 8-12 weeks of age.
Statistical Information
P-Value
< 0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website